Why the study?
It was unknown whether manufacturers' predicted transcatheter heart valve dimensions correspond with actually measured dimensions in patients treated for right ventricular outflow tract insufficiency.
How do actual transcatheter heart valve dimensions measured by IVUS compare to manufacturers' predicted dimensions in patients treated for RVOT insufficiency?
How do actual transcatheter heart valve dimensions measured by IVUS compare to manufacturers' predicted dimensions in patients treated for RVOT insufficiency?
IVUS assessment reveals that actual dimensions of balloon-expandable transcatheter heart valves deployed for RVOT insufficiency differ from manufacturers' predicted charts, with smaller minimal and larger maximal inner diameters.
Discrepancies between predicted and IVUS-measured THV dimensions warrant caution in RVOT cases; leaves open whether imaging guidance improves outcomes.
Introduction Transcatheter heart valve (THV) deployment can be used to treat right ventricular outflow tract (RVOT) insufficiency, but it is unknown whether manufacturers' predicted THV dimensions correspond with actualy measured. Purpose To compare valve frame nominal dimensions predicted by the manufacturers' charts (Melody or Edwards SAPIEN [ES] 3) versus actual dimensions assessed using intravascular ultrasound (IVUS) with Visions PV.035 Digital Catheter (Philips) offering an imaging field of 60mm. Methods IVUS recordings were made post-THV deployment in 6 pts (median age 33 [20–44] yrs, 3 ♀, all with Tetralogy of Fallot) who had undergone prior corrective surgery (4 transannular patch, 1 bioprosthetic valve or 1 pulmonary homograft), but who presented with significant RVOT insufficiency. IVUS-visualized homograft cross-sections were perpendicular to its long axis. Offline volumetric measurements included the inner-THV dimension for a total of 16 evenly spaced cross-sections along the THV length. Assessed were THV inner-frame diameters (minimal and maximal), cross-sectional areas, and cross-sectional area of the visual orifice area identified at the coaptation site (Fig. 1). Each THV (1 Melody [Ø 22mm, 28mm nominal length] and 5 ES3 [1Ø 23mm, 18mm height; 4 Ø 29mm, 22.5mm height]) was implanted after pre-stenting using stents of 36, 39, or 48mm length, deployed on a 24mm (n=1) or 30mm (n=4) balloon-in-balloon catheter. Results Overall, 96 paired cross-sections were analyzed. Actual THV inner area was 95%±20% of that predicted. However, minimum THV inner diameter was smaller, but maximal inner diameter exceeded those predicted (Table 1). The ratios of measured-to-predicted minimal and maximal THV inner diameters were 97%±11% and 112%±13%, respectively, with a measured max/min inner THV frame diameter ratio of 1.16±0.13. However, the ratio of max/min lumen diameter measured at the coaptation site was of 1.11±0.11 signifying low eccentricity. Visual orifice area measured 364.3±87.6 mm2, and was 65%±8% of the measured inner THV area. Conclusions After balloon-expandable THV implantation to treat RVOT insufficiency, there are differences in dimensions between actually measured vs predicated by manufacturers' charts. IVUS allows online tomographic insight into the actual THV frame dimensions and the substantially smaller, but circular orifice area.
No takes yet. Share an insight, caveat, or question.
Kalińczuk et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: